ArticleInflammation2026
Inhibition of TRPV4 Regulates Mitophagy Through the Sirt1/FoxO1 Signaling Pathway To Alleviate Acute Lung Injury.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The transient receptor potential vanilloid 4 (TRPV4) channel has emerged as a key mediator of calcium dysregulation in acute lung injury (ALI), but its role in mitophagy-the selective autophagic clearance of dysfunctional mitochondria-and crosstalk with the Sirtuin 1(Sirt1)signaling axis remain unclear. Lipopolysaccharide (LPS) induced the upregulation of TRPV4, oxidative stress (ROS), and apoptosis in both in vivo and in vitro models. TRPV4 activation (GSK1016790A) exacerbated ALI by impairing mitophagy, as evidenced by reduced LC3/Translocase of the outer mitochondrial membrane 20 (TOMM20) co-localization and decreased PTEN induced kinase 1(PINK1)/PARK2 expression. Conversely, TRPV4 inhibition (GSK2193874) or knockout attenuated lung injury, enhanced mitophagic flux, and reduced mitochondrial damage. Mechanistically, TRPV4 inhibition upregulated Sirt1/Forkhead box O1(FoxO1) signaling, driving PINK1/PARK2-dependent mitophagy. Sirt1 inhibition abrogated these protective effects, confirming its critical role in the TRPV4-mitophagy axis. TRPV4 knockout༈Trpv4⁻/⁻༉mice exhibited reduced pulmonary inflammation, apoptosis, and improved mitochondrial ultrastructure compared to wild-type controls.TRPV4 exacerbated LPS-induced ALI by suppressing Sirt1/FoxO1-mediated mitophagy. Genetic or pharmacological inhibition of TRPV4 restored mitophagic clearance of dysfunctional mitochondria, offering a promising therapeutic strategy for septic ALI. These findings highlighted the TRPV4-Sirt1/FoxO1 axis as a novel target for improving outcomes in critical care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.